Clinical Trial

Study on the Efficacy and Safety of QLM1016 in Schizophrenia

Name: Study on the Efficacy and Safety of QLM1016 in Schizophrenia — clinical trial record (NCT06799559)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 3

View on ClinicalTrials.gov →

Record status

This record was last updated January 29, 2025 (before its estimated July 2026 completion). Its status may not reflect the trial's current state.

Summary

The study will evaluate the antipsychotic efficacy of QLM1016 in a multicenter, randomized, double-blind, parallel controlled study in patients diagnosed with schizophrenia.

Trial Details

NCT Number	NCT06799559
Lead Sponsor	Qilu Pharmaceutical Co., Ltd.
Conditions	Schizophrenia
Enrollment	402 participants
Start Date	2025-05
Primary Completion	2026-07 (estimated)
Study Completion	2026-12 (estimated)
Updated on ClinicalTrials.gov	2025-01-29